Speaking to in-PharmaTechnologist at Pharmapack Europe, CEO Helge Adleff said the company is looking to tailor its parenteral single-use pump – powered only by osmosis – to fit with the delivery needs of potential partners.
He told us that after discussions with several firms, Acuros is already developing different versions of the liquid-dose pump including one with a selectable flow rate, and larger volume forms specifically to meet the demands of the oncology market.
And though the company does not yet have any deals set in stone, Adleff believes that several “interesting talks” with bods at Pharmapack could lead to new ventures.
“There are a lot of potential applications for this device just emerging. New molecules like proteins, RNAs, DNAs, antibodies – most of them need to be given in a constant delivery regime rather than just bolus injection and they need a suitable device,” said Adleff.